Navigation Links
MDA Launches Clinical Network to Speed Myotonic Dystrophy Research

TUCSON, Ariz. (PRWEB) January 23, 2013

The Muscular Dystrophy Association (MDA) has launched a clinical research network that will provide an infrastructure for trials of new treatments for myotonic muscular dystrophy (MMD, also known as DM). The rapid pace of research in this disease was the impetus behind the development of the network.

Each center in the new network has a particular interest and expertise in MMD, and the centers are distributed across the United States to maximize opportunities for participation in studies. Neurologist Charles Thornton at the University of Rochester Medical Center is the overall principal investigator for the network.

There are five university-based centers with expertise in this disorder that make up the network. Their first task will be to determine the usual progression of myotonic dystrophy and the best ways to measure the response of the disease to experimental treatments now in the developmental pipeline.

The five centers are:

Stanford University School of Medicine, Stanford, Calif. | Director: John Day, M.D., Ph.D.

University of Florida College of Medicine, Gainesville, Fla. | Director: Tetsuo Ashizawa, M.D.

University of Kansas Medical Center Research Institute, Kansas City, Kan. | Director: Richard Barohn, M.D.

University of Rochester Medical Center, Rochester, N.Y. | Director: Charles Thornton, M.D.

Ohio State University Medical Center, Columbus, Ohio | Director: John Kissel, M.D.

Network a response to scientific progress

"Recent years have seen rapid progress in the development of molecularly targeted therapy for myotonic dystrophy," said Jane Larkindale, MDA's director of translational research. "Basic research has shown that this disorder involves a disease mechanism known as 'RNA toxicity,' and translational research has shown that this mechanism is unusually responsive to therapeutic intervention. Based on the current pace of therapeutic development, it is reasonable to expect that new therapies will be advanced into clinical trials in the near future, and the new network will ensure that we're prepared for that."

About myotonic muscular dystrophy

Myotonic muscular dystrophy (MMD) is a common form of muscular dystrophy that weakens skeletal muscles and also can affect many other organs in the body, including the heart, eyes, brain and gastrointestinal tract. Caused by an abnormal expansion of DNA on either chromosome 19 or chromosome 3, the disease also is known as "dystrophia myotonica," or "DM."

For more on MMD and current research, see:

About MDA
MDA is the nonprofit health agency dedicated to finding treatments and cures for muscular dystrophy, ALS and related diseases by funding worldwide research. The Association also provides comprehensive health care and support services, advocacy and education.

In addition to funding some 300 research projects worldwide, MDA maintains a national network of 200 medical clinics; facilitates hundreds of support groups for families affected by neuromuscular diseases; and provides local summer camp opportunities for thousands of youngsters living with progressive muscle diseases.

For more information, visit and follow MDA on Facebook ( and Twitter (@MDAnews).

  • MDA-

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. DuPont Pioneer Launches Next Generation T Series Soybeans
2. Launches New Site Design for 2013, Slick New Interface Impresses
3. New EMR Comparison Website Launches Crowdsourcing Electronic Medical Record Software Reviews and Comparisons
4. ActiGraph Launches ActiLife Mobile App
5. Rockingham County Economic Development Launches New Website to Market Research and Tech Park
6. Scout Girl, LLC Launches Website Featuring Vermicomposting Supplies
7. Wysebridge Launches Patent Bar Exam Study Review
8. Junior Varsity Naturals launches sweepstakes with Sweepstakes Ninja
9. UroToday Launches New Prostate Cancer Focused Content Including Immunotherapy for Metastatic Castration-resistant Patients
10. Graphic Design Company, Project6 Design, Launches New Brand And Responsive Website For Innovative Biotech Company PaxVax
11. Bayer CropScience Launches Third Annual Young Farmer Sustainability Award Program
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... device company specializing in imaging technologies, announced today that it ... as part of the Horizon 2020 European Union Framework Programme ... a large-scale clinical trial in breast cancer. , ... , --> --> The ...
(Date:11/25/2015)... LOS ANGELES and HOLLISTON, Mass. ... Regenerative Technology, Inc. (Nasdaq: HART ), a biotechnology ... announced that CEO Jim McGorry will present ... Tuesday, December 1, 2015 at 2:30 p.m. PT. The ... (link below) for 30 days. Management will also be ...
(Date:11/25/2015)... November 25, 2015 The ... is a professional and in-depth study on the ...      (Logo: ) , ... industry including definitions, classifications, applications and industry chain ... the international markets including development trends, competitive landscape ...
(Date:11/24/2015)... -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting ... on Wednesday, December 2 at 9:30 a.m. ET/6:30 a.m. ... will provide a corporate overview. th Annual Oppenheimer ... p.m. ET/10:00 a.m. PT . Jim Mazzola , vice ... overview. --> th Annual Oppenheimer Healthcare Conference in ...
Breaking Biology Technology:
(Date:11/17/2015)... EASTON, Mass. , Nov. 17, 2015 ... a leader in the development and sale of broadly ... the worldwide life sciences industry, today announced it has ... of its $5 million Private Placement (the "Offering"), increasing ... to $4,025,000.  One or more additional closings are expected ...
(Date:11/12/2015)... , Nov. 12, 2015  Arxspan has entered ... MIT and Harvard for use of its ArxLab ... management tools. The partnership will support the institute,s ... and chemical research information internally and with external ... used for managing the Institute,s electronic laboratory notebook, ...
(Date:11/10/2015)... 2015  In this report, the biomarkers ... product, type, application, disease indication, and geography. ... are consumables, services, software. The type segments ... efficacy biomarkers, and validation biomarkers. The applications ... development, drug discovery and development, personalized medicine, ...
Breaking Biology News(10 mins):